<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJMM</journal-id><journal-title-group><journal-title>Open Journal of Medical Microbiology</journal-title></journal-title-group><issn pub-type="epub">2165-3372</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojmm.2015.54030</article-id><article-id pub-id-type="publisher-id">OJMM-62153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Emerging Carbapenem-Resistant &lt;i&gt;Enterobacter cloacae&lt;/i&gt; Producing OXA-48-, VIM- and IMP-Type-&lt;i&gt;β&lt;/i&gt;-Lactamases in Eastern Cape Hospitals in South Africa
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>shika</surname><given-names>Singh-Moodley</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pieter</surname><given-names>Ekermans</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Olga</surname><given-names>Perovic</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa</addr-line></aff><aff id="aff2"><addr-line>National Health Laboratory Service, Port Elizabeth, South Africa</addr-line></aff><aff id="aff3"><addr-line>University of Witwatersrand, Johannesburg, South Africa</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>AshikaS@nicd.ac.za(SS)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>11</month><year>2015</year></pub-date><volume>05</volume><issue>04</issue><fpage>246</fpage><lpage>253</lpage><history><date date-type="received"><day>18</day>	<month>September</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>20</month>	<year>December</year>	</date><date date-type="accepted"><day>23</day>	<month>December</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: 
  Enterobacter cloacae strains have been isolated from Eastern Cape hospitalised patients. Methodology: We have molecularly characterised 
  bla
  <sub>OXA-48-</sub>, 
  bla
  <sub>IMP</sub>- and 
  bla
  <sub>VIM</sub>-expressing 
  E. cloacae isolates demonstrating resistance to carbapenems from five hospitals by multilocus sequence typing. Organism identification and antimicrobial susceptibility testing was done using automated systems and the isolates were screened for carbapenemases using either conventional or real-time PCR and then typed using multilocus sequence typing. Further characterisation of IMP-type-producing 
  E. cloacae isolates, an unusual occurrence in South Africa, was performed by pulsed-field gel electrophoresis. Results and Conclusion: Twenty-five 
  E. cloacae isolates from 24 patients were investigated. Eighteen (72%) isolates harboured either one of the following genes: 
  bla
  <sub>IMP</sub>, 
  bla
  <sub>VIM</sub> or 
  bla
  <sub>OXA-48</sub>. Multilocus sequence typing data and pulsed-field gel electrophoresis showed that several strains from the same geographical region and hospitals were genetically related.
 
</p></abstract><kwd-group><kwd>&lt;i&gt;Enterobacter cloacae&lt;/i&gt;</kwd><kwd> Carbapenem-Producing</kwd><kwd> Multilocus Sequence Typing</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>The increase in the rate of antibiotic resistance is a major concern in isolates from the enterobacteriaceae family. Serious infections caused by extended spectrum β-lactamase-producing enterobacteriaceae are treated with carbapenems, the broadest spectrum of β-lactam antimicrobial agents. Resistance to carbapenems including carbapenemase production is emerging, creating difficulties in the management of life-threatening infections [<xref ref-type="bibr" rid="scirp.62153-ref1">1</xref>] . Amongst the enterobacteriaceae family, Enterobacter species cause a number of hospital acquired infections [<xref ref-type="bibr" rid="scirp.62153-ref2">2</xref>] and Enterobacter cloacae is the most resistant pathogen [<xref ref-type="bibr" rid="scirp.62153-ref3">3</xref>] . The dominant genes contributing to drug resistance in E. cloacae are the plasmid-mediated serine extended spectrum β-lactamase (ESBL) bla<sub>CTX-M</sub>; the serine carbapenemase bla<sub>KPC</sub> and the metallo-β-lacatamases (MBLs) bla<sub>NDM</sub>, bla<sub>IMP</sub> and bla<sub>VIM</sub> [<xref ref-type="bibr" rid="scirp.62153-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.62153-ref5">5</xref>] . The acquired MBL, bla<sub>IMP-1</sub> emerged and spread in Gram-negative bacilli in Japan in the early 1990s [<xref ref-type="bibr" rid="scirp.62153-ref6">6</xref>] and together with its variants have since been detected in other countries worldwide [<xref ref-type="bibr" rid="scirp.62153-ref7">7</xref>] -[<xref ref-type="bibr" rid="scirp.62153-ref12">12</xref>] . bla<sub>VIM-1</sub> was first reported in Italy, also in the 1990s [<xref ref-type="bibr" rid="scirp.62153-ref13">13</xref>] . Like bla<sub>IMP</sub>, variants of this gene have been detected globally [<xref ref-type="bibr" rid="scirp.62153-ref14">14</xref>] -[<xref ref-type="bibr" rid="scirp.62153-ref18">18</xref>] . These genes are located on plasmids that enhance their ability to spread horizontally making treatment of infections more challenging. The production of IMP and VIM β-lactamases in the hospital environment has become a serious concern [<xref ref-type="bibr" rid="scirp.62153-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.62153-ref20">20</xref>] . In South Africa, the emergence of bla<sub>NDM</sub>, bla<sub>KPC</sub>, bla<sub>VIM</sub> and bla<sub>OXA-48</sub> and its variants produced by enterobacteriaceae have been reported [<xref ref-type="bibr" rid="scirp.62153-ref21">21</xref>] -[<xref ref-type="bibr" rid="scirp.62153-ref23">23</xref>] . However, to our knowledge there are no studies that document bla<sub>IMP</sub> genes in E. cloacae in South Africa. In this study, we identified E. cloacae isolates harbouring IMP, VIM and OXA-48 enzymes and assessed strain clonality to determine whether they were genetically related.</p></sec><sec id="s2"><title>2. Methodology</title><p>Carbapenem non-susceptible enterobacteriaceae isolates were submitted to the Antimicrobial Resistance Laboratory at the National Institute for Communicable Diseases for confirmation of carbapenemase-producing enterobacteriaceae (CPE) genes. Upon receipt, organisms were retested for identification and antimicrobial susceptibility testing using automated systems (VITEK<sup>&#174;</sup> II (bioM&#232;rieux, France) and/or the Microflex MALDI-ToF (BrukerDaltonik, GmbH) and the MicroScan<sup>&#174;</sup> Walkaway system (Siemens, USA) respectively). The interpretation of susceptibility was done according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [<xref ref-type="bibr" rid="scirp.62153-ref24">24</xref>] . DNA was extracted using a crude boiling method at 95˚C for 25 minutes. The supernatant was harvested and screened for bla<sub>NDM</sub>, bla<sub>KPC</sub> and bla<sub>OXA-48</sub> and its variants using real-time polymerase chain reaction (PCR) (LightCycler 480 II, Roche Applied Science, LightCycler 480 Probes Master kit, Roche Diagnostics, IN USA) and the Centre for Disease Control and Prevention (CDC) protocol primers for detection of bla<sub>NDM</sub> and bla<sub>KPC</sub> and the following primers and probes for bla<sub>OXA-48</sub> which was designed for this study: OXA-48Fvariant5’- gCgTggTTAAggATgAACAC-3’,OXA-48Svariant5’-CATYTCgggCAATgTAgACAg-3’, OXA-48Rvariant 5’- gATgTgggCATATCCATATTCATCgCA-3’ and OXA-48probe 5’-CY5-CATTggCTTCggTCAgCATggCT- BBQ-3’. The screening of bla<sub>GES</sub>, bla<sub>IMP</sub> and bla<sub>VIM</sub> was done using conventional PCR (GStorm Thermal Cycler, Somerton Biotechnology Centre, UK and the Qiagen multiplex PCR kit, Qiagen, Germany) and the primers from previous publications [<xref ref-type="bibr" rid="scirp.62153-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.62153-ref26">26</xref>] . Multilocus sequencing (MLST) was performed on these isolates using previously published primers and conventional typing methods [<xref ref-type="bibr" rid="scirp.62153-ref27">27</xref>] . Conventional PCR was performed for each of the seven reference/house-keeping genes and the products were purified (Qiagen Purification kit; Qiagen, Germany) and sequenced (Inqaba Biotech, South Africa). Sequences were analysed using the online database (http://pubmlst.org/) and analysis tools (http://pubmlst.org/analysis/). For the 15 IMP-producing E. cloacae isolates identified by conventional PCR, pulsed-field gel electrophoresis (PFGE) using the XbaI restriction enzyme (Thermo Scientific, MA USA) was performed. Electrophoresis was performed on 1% PFGE agarose gel with a CHEF-DR III electrophoresis system (Bio-Rad Laboratories, Richmond, CA, USA). Clustering was done according to Tenover criteria [<xref ref-type="bibr" rid="scirp.62153-ref28">28</xref>] , and a cluster was defined as unique PFGE patterns differing by 3 or less bands.</p></sec><sec id="s3"><title>3. Results and Discussion</title><p>From January 2013 to April 2014, eighteen of twenty-five E. cloacae isolates from twenty-four patients at five hospitals in the Eastern Cape harboured either one of the following genes: bla<sub>IMP</sub>, bla<sub>VIM</sub> or bla<sub>OXA-</sub><sub>48</sub> resulting in further investigation. Isolates were obtained from clinical specimens: urine (n = 8), sputum (n = 1), pus swab (n = 7), catheter (n = 1) and other sterile body fluids (n = 8). Demographic analysis showed that 13 (54%) were male and 11 (46%) were female. The mean age was 40.75 years (including one neonate). Based on antimicrobial susceptibility testing, majority of the isolates were non-susceptible to ertapenem (96%) and all were susceptible to imipenem and meropenem. The MIC<sub>50</sub> and MIC<sub>90</sub> for ertapenem were 2 and ≥4 respectively and ≤1 for imipenem and meropenem for both values. Fifteen isolates harboured bla<sub>IMP</sub>, two contained bla<sub>VIM</sub> and one contained bla<sub>OXA-48</sub>. The remaining seven did not express any of the genes tested. All seven of the PCR-negative isolates were non-susceptible to ertapenem. One isolate positive for bla<sub>VIM</sub> was fully susceptible to the carbapenem group of antibiotics.</p><p>The MLST scheme performed in this study is a new scheme developed and published in 2013 [<xref ref-type="bibr" rid="scirp.62153-ref27">27</xref>] and we were not able to compare the sequence types (ST) obtained in this study to previous sequence types obtained for this organism in South Africa. Five isolates resulted in new sequence types as they have not been located on the database although allelic profiles were generated for all seven reference genes. To our knowledge, this study provides novel information regarding MLST data for E. cloacae in South Africa. MLST results show that horizontal transmission of bacteria in the hospital setting is potentially an important factor to consider. <xref ref-type="fig" rid="fig1">Figure 1</xref> illustrates a timeline describing the isolates from each hospital over a 16 month period and based on the STs observed, horizontal transmission is possible. Phylogenetic analysis revealed that all strains shared a common ancestor and were distantly related as evidenced by the different number of STs detected. Those belonging to the same ST clustered together. Identical STs within the same hospital and among different hospitals could indicate intra- and inter-clonal spread. This information therefore suggests that the isolates are related phylogenetically but does not necessarily infer transmission. The limitation of using a methodology like MLST which investigates a relatively small number of reference genes is that there is substantial genetic diversity within a single species group. Therefore, the use of whole genome sequencing would provide a better understanding of transmission events and genetic relatedness. Another limitation of this study is that we had little epidemiological and clinical data. We were not able to obtain information regarding treatment regimens for the patients and therefore cannot comment on previous exposure to carbapenems.</p><p>IMP-type-producing E. cloacae have been documented globally, for example in the United Kingdom, the Far East and Australia [<xref ref-type="bibr" rid="scirp.62153-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.62153-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.62153-ref29">29</xref>] . To the best of our knowledge, the occurrence of bla<sub>IMP</sub> genes in E. cloacae isolates is an unusual finding in South Africa. Majority (n = 15) of the 18 isolates that were PCR-positive for carbapenemase-producing genes, harboured bla<sub>IMP</sub>. MLST data for three isolates was not obtained due to sequencing technicalities, four belonged to ST124, four belonged to ST90, two belonged to a new sequence type and displayed identical allelic profiles and, the remaining two belonged to ST93 and ST108. Relatively little is known about IMP-type MBL-producing E. cloacae with regards to prevalence, risk factors and clinical effects [<xref ref-type="bibr" rid="scirp.62153-ref8">8</xref>] and although our clinical and epidemiological data is scarce some information can be utilised. The specimen types for these infections were fluid/aspirate (n = 5; 33%), pus swab (n = 5; 33%), urine (n = 3; 20%) and catheter tip and sputum (n = 1; 7% each). Eight (53%) patients had bacteria other than IMP-type-producing E. cloacae isolated from the same culture specimen i.e. polymicrobial isolation. Susceptibility to antimicrobial agents is presented in <xref ref-type="table" rid="table1">Table 1</xref>.The minimal inhibitory concentration (MIC) breakpoints for imipenem and meropenem were not elevated and was in the susceptible range &lt; 1 for these isolates. Similar findings were observed in the study by Hayakawa et al., in 2014 underscoring the difficulties in identifying metallo-β-carbapenemase-pro- ducing organisms primarily based on MIC results [<xref ref-type="bibr" rid="scirp.62153-ref8">8</xref>] . This could also be used as a possible explanation for the one bla<sub>VIM</sub>-positive isolate that was fully susceptible to the carbapenem group of antibiotics in our study.</p><p>Further investigation of the IMP-type-producing E. cloacae isolates using PFGE for strain comparison was performed using the Bionumerics v 6.5 software (Applied Maths, Belgium). Three major clusters were identified. Clustering was done according to Tenover criteria [<xref ref-type="bibr" rid="scirp.62153-ref28">28</xref>] ), and a cluster was defined as PFGE patterns differing by 3 or less bands. The isolates from Cluster A were indistinguishable (no band differences). These included ML0087, ML0279 and ML0207. Cluster B consisted of three isolates that were indistinguishable (ML0197, ML0198 and ML0203). Cluster C consisted of ML0269, ML0280, ML0299 and ML0330. Slight band differences are seen but the patterns were highly similar (more than 90%) (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The remaining five isolates are related but do not fall within the three major clusters (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>Moreover, these 15 IMP-producing E. cloacae strains were analysed on the Microflex MALDI-ToF instrument and compared using the Flex analysis software (Bruker Daltonik, GmbH). All 15 isolates identified with the same E. cloacae reference strain with high confidence. The spectra generated showed that all 15 isolates were similar. Mass peaks of the proteins were comparable and there were no mass protein shifts identified between the isolates. Additionally, the dendograms generated showed that all 15 isolates have the same origin. Two major clusters could be seen with further sub-clustering (<xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><fig-group id="fig1"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title>Timeline of Enterobacter cloacae isolates from five hospitals in the Eastern Cape from January 2013 to April 2014.</title></caption><fig id ="fig1_1"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/12-2260199x7.png"/></fig></fig-group><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title>Antimicrobial susceptibility testing for 15 IMP-type-producing Enterobacter cloacae isolates</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Antibiotics</th><th align="center" valign="middle" >Susceptible (n, %)</th><th align="center" valign="middle" >Intermediate (n, %)</th><th align="center" valign="middle" >Resistant (n, %)</th></tr></thead><tr><td align="center" valign="middle" >Amikacin</td><td align="center" valign="middle" >15 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Amox/K Clav</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >15 (100)</td></tr><tr><td align="center" valign="middle" >Amp/ Sulbactam</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >15 (100)</td></tr><tr><td align="center" valign="middle" >Ampicillin</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >15 (100)</td></tr><tr><td align="center" valign="middle" >Aztreonam</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >15 (100)</td></tr><tr><td align="center" valign="middle" >Cefepime</td><td align="center" valign="middle" >3 (20)</td><td align="center" valign="middle" >3 (20)</td><td align="center" valign="middle" >9 (60)</td></tr><tr><td align="center" valign="middle" >Cefotaxime</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >15 (100)</td></tr><tr><td align="center" valign="middle" >Cefoxitin</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >15 (100)</td></tr><tr><td align="center" valign="middle" >Ceftazidime</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >15 (100)</td></tr><tr><td align="center" valign="middle" >Cefuroxime</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >15 (100)</td></tr><tr><td align="center" valign="middle" >Chloramphenicol</td><td align="center" valign="middle" >9 (60)</td><td align="center" valign="middle" >1 (7)</td><td align="center" valign="middle" >5 (33)</td></tr><tr><td align="center" valign="middle" >Ciprofloxacin</td><td align="center" valign="middle" >5 (33)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >10 (67)</td></tr><tr><td align="center" valign="middle" >Colistin</td><td align="center" valign="middle" >15 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Ertapenem</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >7 (47)</td><td align="center" valign="middle" >8 (53)</td></tr><tr><td align="center" valign="middle" >Fosfomycin</td><td align="center" valign="middle" >13 (87)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2 (13)</td></tr><tr><td align="center" valign="middle" >Gentamicin</td><td align="center" valign="middle" >5 (33)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >10 (67)</td></tr><tr><td align="center" valign="middle" >Imipenem</td><td align="center" valign="middle" >15 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Levofloxacin</td><td align="center" valign="middle" >10 (67)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >5 (33)</td></tr><tr><td align="center" valign="middle" >Meropenem</td><td align="center" valign="middle" >15 (100)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Pip/Tazo</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >4 (27)</td><td align="center" valign="middle" >11 (73)</td></tr><tr><td align="center" valign="middle" >Piperacillin</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >15 (100)</td></tr><tr><td align="center" valign="middle" >Tetracycline</td><td align="center" valign="middle" >6 (40)</td><td align="center" valign="middle" >1 (7)</td><td align="center" valign="middle" >8 (53)</td></tr><tr><td align="center" valign="middle" >Tigecycline</td><td align="center" valign="middle" >9 (60)</td><td align="center" valign="middle" >1 (7)</td><td align="center" valign="middle" >5 (33)</td></tr><tr><td align="center" valign="middle" >Tobramycin</td><td align="center" valign="middle" >5 (33)</td><td align="center" valign="middle" >1 (7)</td><td align="center" valign="middle" >9 (60)</td></tr><tr><td align="center" valign="middle" >Trimeth/Sulfa</td><td align="center" valign="middle" >1 (7)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >14 (93)</td></tr></tbody></table></table-wrap><fig-group id="fig2"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> PFGE dendogram and electrophoresis gel pattern for IMP-type-producing Enterobacter cloacae isolates.</title></caption><fig id ="fig2_1"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/12-2260199x8.png"/></fig></fig-group><fig id="fig3"  position="float"><label><xref ref-type="fig" rid="fig3">Figure 3</xref></label><caption><title> MALDI-ToF dendogram for 15 IMP-type-producing Enterobacter cloacae isolates</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/12-2260199x9.png"/></fig><p>The majority of the isolates appear clonally related by MLST. The dendogram generated by mass spectrometry of the 15 IMP-producing isolates indicate that the strains are highly related and PFGE of these 15 isolates identified three major clusters indicating that the strains were related. The possibility that mobile genetic elements may have been transferred among strains possessing the same drug-resistant gene does exist but the exact mechanisms of acquisition are not certain. It is also not known if the strains possessed the same subtype i.e. IMP-type genes or variants thereof.</p><p>Moreover, it is interesting to note that when the 15 IMP-type-producing E. cloacae isolates were screened for bla<sub>IMP</sub> using real-time PCR, LightCycler 480 II, Roche Applied Science, LightCycler 480 Probes Master kit and the LightMix Modular IMP (ESBL) kit(Roche Diagnostics, IN, USA), bla<sub>IMP</sub> was not detected in any of these isolates. This may be because the kit is able to detect at least IMP-9, 16, 18, 22 and 25 only. With the conventional PCR used originally in this study, primers from a previous publication were used and were designed from reference sequences downloaded from Genbank to obtain multiple variants [<xref ref-type="bibr" rid="scirp.62153-ref25">25</xref>] . It appears that the latter method is more sensitive to a wider range of IMP variants. Should this prove true, IMP variants are not being detected due to limitations in the methodology resulting in an under-reporting of IMP-type producing E. cloacae variants in South Africa.</p></sec><sec id="s4"><title>4. Conclusion</title><p>From this study, we can conclude that MBL-producing strains are prevalent in the Eastern Cape hospitals. Further investigation of 15 IMP-producing E. cloacae isolates, currently an unusual occurrence in South Africa, revealed that majority of the isolates did appear related within three major clusters.</p></sec><sec id="s5"><title>Acknowledgements</title><p>We thank Ms. Marshagne Smith, Ms. Ruth Mohlabeng, Ms. Rubeina Badat, Ms. Gloria Molaba and Ms. Naseema Bulbulia for assistance with the laboratory work and Ms. Penny Crowther for assistance with the database. We also thank the Centre for Enteric Diseases, National Institute for Communicable Diseases for the use of the PFGE equipment.</p></sec><sec id="s6"><title>Cite this paper</title><p>AshikaSingh-Moodley,PieterEkermans,OlgaPerovic, (2015) Emerging Carbapenem-ResistantEnterobacter cloacae Producing OXA-48-, VIM- and IMP-Type-β-Lactamases in Eastern Cape Hospitals in South Africa. Open Journal of Medical Microbiology,05,246-253. doi: 10.4236/ojmm.2015.54030</p></sec><sec id="s7"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.62153-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Yong, D., et al. (2009) Characterization of a New Metallo-Beta-Lactamase Gene, bla(NDM-1), and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India. Antimicrobial Agents and Chemotherapy, 53, 5046-5054. http://dx.doi.org/10.1128/AAC.00774-09</mixed-citation></ref><ref id="scirp.62153-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ren, Y., et al. (2010) Complete Genome Sequence of Enterobacter cloacae Subsp. Cloacae Type Strain ATCC 13047. Journal of Bacteriology, 192, 2463-2464. http://dx.doi.org/10.1128/JB.00067-10</mixed-citation></ref><ref id="scirp.62153-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Mezzatesta, M.L., Gona, F. and Stefani, S. (2012) Enterobacter cloacae Complex: Clinical Impact and Emerging Antibiotic Resistance. Future Microbiology, 7, 887-902. http://dx.doi.org/10.2217/fmb.12.61</mixed-citation></ref><ref id="scirp.62153-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Bush, K. (2010) Alarming Beta-Lactamase-Mediated Resistance in Multidrug-Resistant Enterobacteriaceae. Current Opinion in Microbiology, 13, 558-564. http://dx.doi.org/10.1016/j.mib.2010.09.006</mixed-citation></ref><ref id="scirp.62153-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Heller, I., Grif, K. and Orth, D. (2012) Emergence of VIM-1-Carbapenemase-Producing Enterobacter cloacae in Tyrol, Austria. Journal of Medical Microbiology, 61, 567-571. http://dx.doi.org/10.1099/jmm.0.038646-0</mixed-citation></ref><ref id="scirp.62153-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Osano, E., et al. (1994) Molecular Characterization of an Enterobacterial Metallo Beta-Lactamase Found in a Clinical Isolate of Serratia marcescens That Shows Imipenem Resistance. Antimicrobial Agents and Chemotherapy, 38, 71-78. http://dx.doi.org/10.1128/AAC.38.1.71</mixed-citation></ref><ref id="scirp.62153-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Gibb, A.P., et al. (2002) Nosocomial Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa with a New bla(IMP) Allele, bla(IMP-7). Antimicrobial Agents and Chemotherapy, 46, 255-258. http://dx.doi.org/10.1128/AAC.46.1.255-258.2002</mixed-citation></ref><ref id="scirp.62153-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hayakawa, K., et al. (2014) Molecular and Epidemiological Characterization of IMP-Type Metallo-Beta-Lactamase-Producing Enterobacter cloacae in a Large Tertiary Care Hospital in Japan. Antimicrobial Agents and Chemotherapy, 58, 3441-3450. http://dx.doi.org/10.1128/AAC.02652-13</mixed-citation></ref><ref id="scirp.62153-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ho, S.E., et al. (2002) Carbapenem-Resistant Pseudomonas aeruginosa in Malaysia Producing IMP-7 Beta-Lactamase. Antimicrobial Agents and Chemotherapy, 46, 3286-3287. http://dx.doi.org/10.1128/AAC.46.10.3286-3287.2002</mixed-citation></ref><ref id="scirp.62153-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hrabák, J. and Cervená, D. (2011) Regional Spread of Pseudomonas aeruginosa ST357 Producing IMP-7 Metallo-β-Lactamase in Central Europe. Journal of Clinical Microbiology, 49, 474-475. http://dx.doi.org/10.1128/JCM.00684-10</mixed-citation></ref><ref id="scirp.62153-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Leung, G.H., Gray, T.J., Cheong, E.Y., Haertsch, P. and Gottlieb, T. (2013) Persistence of Related bla-IMP-4 Metallo-Betalactamase Producing Enterobacteriaceae from Clinical and Environmental Specimens within a Burns Unit in Australia—A Six-Year Retrospective Study. Antimicrobial Resistance and Infection Control, 2, 35.</mixed-citation></ref><ref id="scirp.62153-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Naas, T., Cuzon, G., Bogaerts, P., Glupczynski, Y. and Nordmann, P. (2011) Evaluation of a DNA Microarray (Check-MDR CT102) for Rapid Detection of TEM, SHV, and CTX-M Extended-Spectrum Beta-Lactamases and of KPC, OXA-48, VIM, IMP, and NDM-1 Carbapenemases. Journal of Clinical Microbiology, 49, 1608-1613. http://dx.doi.org/10.1128/JCM.02607-10</mixed-citation></ref><ref id="scirp.62153-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Lauretti, L., Riccio, M.L., Mazzariol, A., Cornaglia, G., Amicosante, G., Fontana, R. and Rossolini, G.M. (1999) Cloning and Characterization of blaVIM, a New Integron-Borne Metallo-Beta-Lactamase Gene from a Pseudomonas aeruginosa Clinical Isolate. Antimicrobial Agents and Chemotherapy, 43, 1584-1590.</mixed-citation></ref><ref id="scirp.62153-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Cardoso, O., Leit&amp;atildeo, R., Figueiredo, A., Sousa, J.C., Duarte, A. and Peixe, L.V. (2002) Metallo-Beta-Lactamase VIM-2 in Clinical Isolates of Pseudomonas aeruginosa from Portugal. Microbial Drug Resistance, 8, 93-97. http://dx.doi.org/10.1089/107662902760190635</mixed-citation></ref><ref id="scirp.62153-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Lee, K., Lim, J.B., Yum, J.H., Yong, D., Chong, Y., Kim, J.M. and Livermore, D.M. (2002) blaVIM-2 Cassette-Containing Novel Integrons in Metallo-Beta-Lactamase-Producing Pseudomonas aeruginosa and Pseudomonas putida Isolates Disseminated in a Korean Hospital. Antimicrobial Agents and Chemotherapy, 46, 1053-1058. http://dx.doi.org/10.1128/AAC.46.4.1053-1058.2002</mixed-citation></ref><ref id="scirp.62153-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Pournaras, S., Tsakris, A., Maniati, M., Tzouvelekis, L.S. and Maniatis, A.N. (2002) Novel Variant (blaVIM-4) of the Metallo-Beta-Lactamase Gene blaVIM-1 in a Clinical Strain of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 46, 4026-4028. http://dx.doi.org/10.1128/AAC.46.12.4026-4028.2002</mixed-citation></ref><ref id="scirp.62153-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Toleman, M.A., Rolston, K., Jones, R.N. and Walsh, T.R. (2002) Molecular Characterization of VIM-4, a Novel Metallo-Beta-Lactamaseisolated from Texas: Report from the Cancer Surveillance Program (2001). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 27-30 September 2002.</mixed-citation></ref><ref id="scirp.62153-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yan, J.-J., Hsueh, P.-R., Ko, W.-C., Luh, K.-T., Tsai, S.-H., Wu, H.-M. and Wu, J.-J. (2001) Metallo-Beta-Lactamases in Clinical Pseudomonas Isolates in Taiwan and Identification of VIM-3, a Novel Variant of the VIM-2 Enzyme. Antimicrobial Agents and Chemotherapy, 45, 2224-2228. http://dx.doi.org/10.1128/AAC.45.8.2224-2228.2001</mixed-citation></ref><ref id="scirp.62153-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Poirel, L., Naas, T., Nicolas, D., Collet, L., Bellais, S., Cavallo, J.-D. and Nordmann, P. (2000) Characterization of VIM-2, a Carbapenem-Hydrolyzing Metallo-Beta-Lactamase and Its Plasmid- and Integron-Borne Gene from a Pseudomonas aeruginosa Clinical Isolate in France. Antimicrobial Agents and Chemotherapy, 44, 891-897. http://dx.doi.org/10.1128/AAC.44.4.891-897.2000</mixed-citation></ref><ref id="scirp.62153-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Richet, H.M., Mohammed, J., McDonald, L.C. and Jarvis, W.R. (2001) Building Communication Networks: International Network for the Study and Prevention of Emerging Antimicrobial Resistance. Emerging Infectious Diseases, 7, 319-322. http://dx.doi.org/10.3201/eid0702.010235</mixed-citation></ref><ref id="scirp.62153-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Brink, A.J., Coetzee, J., Clay, C.G., Sithole, S., Richards, G.A., Poirel, L. and Nordmann, P. (2011) Emergence of New Delhi Metallo-Beta-Lactamase (NDM-1) and Klebsiella pneumoniae Carbapenemase (KPC-2) in South Africa. Journal of Clinical Microbiology, 50, 525-527. http://dx.doi.org/10.1128/JCM.05956-11</mixed-citation></ref><ref id="scirp.62153-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Brink, A.J., Coetzee, J., Corcoran, C., Clay, C.G., Hari-Makkan, D., Jacobson, R.K., et al. (2013) Emergence of OXA-48 and OXA-181 Carbapenemases among Enterobacteriaceae in South Africa and Evidence of in Vivo Selection of Colistin Resistance as a Consequence of Selective Decontamination of the Gastrointestinal Tract. Journal of Clinical Microbiology, 51, 369-372. http://dx.doi.org/10.1128/JCM.02234-12</mixed-citation></ref><ref id="scirp.62153-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Peirano, G., Moolman, J., Pitondo-Silva, A. and Pitout, J.D.D. (2012) The Characteristics of VIM-1-Producing Klebsiella pneumoniae from South Africa. Scandinavian Journal of Infectious Diseases, 44, 74-78. http://dx.doi.org/10.3109/00365548.2011.614276</mixed-citation></ref><ref id="scirp.62153-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">CLSI (2013) Clinical and Laboratory Standards Institute (CLSI) Guidelines—Performance Standards for Antimicrobial Susceptibility Testing. CLSI Document M100.</mixed-citation></ref><ref id="scirp.62153-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Mendes, R.E., Kiyota, K.A., Monteiro, J., Castanheira, M., Andrade, S.S., Gales, A.C., Pignatari, A.C.C. and Tufik, S. (2007) Rapid Detection and Identification of Metallo-Beta-Lactamase-Encoding Genes by Multiplex Real-Time PCR Assay and Melt Curve Analysis. Journal of Clinical Microbiology, 45, 544-547. http://dx.doi.org/10.1128/JCM.01728-06</mixed-citation></ref><ref id="scirp.62153-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Queenan, A.M. and Bush, K. (2007) Carbapenemases: The Versatile Beta-Lactamases. Clinical Microbiology Reviews, 20, 440-458. http://dx.doi.org/10.1128/CMR.00001-07</mixed-citation></ref><ref id="scirp.62153-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Miyoshi-Akiyama, T., Hayakawa, K., Ohmagari, N., Shimojima, M. and Kirikae, T. (2013) Multilocus Sequence Typing (MLST) for Characterization of Enterobacter cloacae. PLoS ONE, 8, e66358. http://dx.doi.org/10.1371/journal.pone.0066358</mixed-citation></ref><ref id="scirp.62153-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Tenover, F.C., Arbeit, R.D., Goering, R.V., Mickelsen, P.A., Murray, B.E., Persing, D.H. and Swaminathan, B. (1995) Interpreting Chromosomal DNA Restriction Patterns Produced by Pulsed-Field Gel Electrophoresis: Criteria for Bacterial Strain Typing. Journal of Clinical Microbiology, 33, 2233-2239.</mixed-citation></ref><ref id="scirp.62153-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Shet, V., Gouliouris, T., Brown, N.M., Turton, J.F., Zhang, J. and Woodford, N. (2011) IMP Metallo-β-Lactamase-Producing Clinical Isolates of Enterobacter cloacae in the UK. Journal of Antimicrobial Chemotherapy, 66, 1408-1409. http://dx.doi.org/10.1093/jac/dkr078</mixed-citation></ref></ref-list></back></article>